Abbott Laboratories SG&A Expenses 2010-2025 | ABT
Abbott Laboratories annual/quarterly sg&a expenses history and growth rate from 2010 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Abbott Laboratories sg&a expenses for the quarter ending March 31, 2025 were $3.061B, a 3.45% increase year-over-year.
- Abbott Laboratories sg&a expenses for the twelve months ending March 31, 2025 were $11.799B, a 5.86% increase year-over-year.
- Abbott Laboratories annual sg&a expenses for 2024 were $11.697B, a 6.83% increase from 2023.
- Abbott Laboratories annual sg&a expenses for 2023 were $10.949B, a 2.66% decline from 2022.
- Abbott Laboratories annual sg&a expenses for 2022 were $11.248B, a 0.67% decline from 2021.
| Abbott Laboratories Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024 | $11,697 |
| 2023 | $10,949 |
| 2022 | $11,248 |
| 2021 | $11,324 |
| 2020 | $9,696 |
| 2019 | $9,765 |
| 2018 | $9,744 |
| 2017 | $9,182 |
| 2016 | $6,736 |
| 2015 | $6,785 |
| 2014 | $6,530 |
| 2013 | $6,372 |
| 2012 | $6,735 |
| 2011 | $7,365 |
| 2010 | $10,376 |
| 2009 | $8,406 |
| Abbott Laboratories Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2025-03-31 | $3,061 |
| 2024-12-31 | $2,907 |
| 2024-09-30 | $2,895 |
| 2024-06-30 | $2,936 |
| 2024-03-31 | $2,959 |
| 2023-12-31 | $2,724 |
| 2023-09-30 | $2,723 |
| 2023-06-30 | $2,740 |
| 2023-03-31 | $2,762 |
| 2022-12-31 | $2,973 |
| 2022-09-30 | $2,731 |
| 2022-06-30 | $2,757 |
| 2022-03-31 | $2,787 |
| 2021-12-31 | $3,048 |
| 2021-09-30 | $2,767 |
| 2021-06-30 | $2,726 |
| 2021-03-31 | $2,783 |
| 2020-12-31 | $2,570 |
| 2020-09-30 | $2,302 |
| 2020-06-30 | $2,276 |
| 2020-03-31 | $2,548 |
| 2019-12-31 | $2,413 |
| 2019-09-30 | $2,440 |
| 2019-06-30 | $2,434 |
| 2019-03-31 | $2,478 |
| 2018-12-31 | $2,359 |
| 2018-09-30 | $2,377 |
| 2018-06-30 | $2,466 |
| 2018-03-31 | $2,542 |
| 2017-12-31 | $2,477 |
| 2017-09-30 | $2,115 |
| 2017-06-30 | $2,150 |
| 2017-03-31 | $2,440 |
| 2016-12-31 | $1,673 |
| 2016-09-30 | $1,628 |
| 2016-06-30 | $1,737 |
| 2016-03-31 | $1,698 |
| 2015-12-31 | $1,655 |
| 2015-09-30 | $1,666 |
| 2015-06-30 | $1,727 |
| 2015-03-31 | $1,737 |
| 2014-12-31 | $1,666 |
| 2014-09-30 | $1,595 |
| 2014-06-30 | $1,649 |
| 2014-03-31 | $1,620 |
| 2013-12-31 | $1,260 |
| 2013-09-30 | $1,612 |
| 2013-06-30 | $1,714 |
| 2013-03-31 | $1,786 |
| 2012-12-31 | $1,159 |
| 2012-09-30 | $1,920 |
| 2012-06-30 | $1,814 |
| 2012-03-31 | $1,842 |
| 2011-12-31 | $2,905 |
| 2011-09-30 | $4,239 |
| 2011-06-30 | $2,762 |
| 2011-03-31 | $2,850 |
| 2010-12-31 | $2,797 |
| 2010-09-30 | $2,673 |
| 2010-06-30 | $2,743 |
| 2010-03-31 | $2,162 |
| 2009-12-31 | $2,225 |
| 2009-09-30 | $2,086 |
| 2009-06-30 | $2,024 |
| 2009-03-31 | $2,071 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $231.085B | $41.950B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||